HOBOKEN, NJ-- via eTeligis - Optigenex Inc. (OTC Pink: OPGX) announced today the results of a pilot study entitled "A Proof of Concept Study for a Randomized Double-Blind, Placebo Controlled, Parallel Group, Efficacy Study of AlphaBrain™ administered orally," conducted by the Boston Center for Memory. The purpose of the study was to test the efficacy of AlphaBrain™ with ac-11® as an enhancer of cognitive ability, including memory, attention, problem solving and reasoning.
Developed by Optigenex, AC-11® is a patented, all natural rain forest botanical extract shown to help the body's natural ability to repair damaged DNA. The Onnit-sponsored study, which utilized a methodology and study design similar to that applied in new drug evaluations, but not often used in research to evaluate dietary supplements, demonstrated statistically significant improvements in areas related to memory and "executive function" (e.g., reasoning and problem solving) among the test subject volunteers taking AlphaBrain™ with ac-11®.
Anthony Worth, Managing Director of Optigenex, said, "We are delighted by the findings. Prior research had shown a marked promise for ac-11® in the areas of neuro-protection and neuro-enhancement. But now, in a carefully planned and well focused study, Onnit and the Boston Center for Memory have teamed up to generate reliable data points showing the unique way in which AlphaBrain™ with ac-11® works to enhance cognitive function. The results from the study are impressive enough, moreover, to confirm our long standing belief that ac-11® works synergistically with the other beneficial neuro-nutrients found in the AlphaBrain™ formula to further enhance the benefits we previously have seen with ac-11® alone."
Discussing the company's relationship with Onnit, Mr. Worth added, "Since early 2010, Onnit's track record of growth in sales and industry influence, from essentially nil as 'just another on-line startup' to extraordinary as a rising leader in cutting edge health care products, has been, from our perspective, nothing short of stunning. That growth has come in large part from Onnit's many satisfied customers, young and old, who almost literally form a 'community' centered around Onnit's progressive, and yet quite sound, wellness philosophy. The fact that Onnit's management is focused on new research and not simply content to rest on its customer-driven success demonstrates its commitment to a solid foundation for future growth. And in that regard, while we are very pleased with the work that has been done at the Boston Center, we look forward to seeing the results from a larger study currently underway utilizing new benchmarks that both we and Onnit believe will provide deeper insights into the mechanisms of action in play when AlphaBRAIN™ with ac-11® is taken by healthy individuals."
Aubrey Marcus, CEO of Onnit Labs, LLC, said, "AC-11® is the epitome of the type of ingredient we look for in creating our formulas. Sourced from an Earth-grown nutrient (Uncaria tomentosa) and elevated to a highly potent and unique compound through natural, non-chemical methods, ac-11® is the perfect blend of nature and science. As a key ingredient in the proprietary AlphaBRAIN™ formula, we believe ac-11® plays a fundamental role in enhancing the efficacy of the other ingredients, while also helping to provide a greater sense of mental vitality."
To view the results of the study, please visit: https://www.onnit.com/clinical-studies/alpha-brain-clinical-trial/
About Optigenex Inc.:
Optigenex is a formulator, distributor and provider of proprietary next generation, dietary supplements, skin care products and bulk ingredient featuring ac-11® as its core platform technology. AC-11® (formerly known as C-MED-100®) is a patented, bioactive and water soluble rain forest ingredient derived from the medicinal herb Uncaria tomentosa. For more information about Optigenex, please visit: www.optigenex.com
About Onnit Labs LLC:
Onnit is an Austin, TX based health and wellness company focused on encouraging peak human performance through a combination of unique products and actionable information. With strategies from leading professional athletes and medical practitioners, Onnit is committed to creating naturally derived nutritional supplements and functional foods based upon the latest ingredient science and dietary research. For more information visit: www.Onnit.com or contact Orlando@Onnit.com.
*The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to treat, diagnose, cure or prevent any disease.
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) increased costs, including from increased raw material or energy prices, (iii) changes in general worldwide economic or political conditions, (iv) adverse publicity or negative consumer perception regarding nutritional supplements, (v) issues with obtaining raw materials of adequate quality or quantity, (vi) litigation and claims, including product liability, intellectual property and other types, (vii) disruptions from or following acquisitions including the loss of customers, (viii) increased competition, (ix) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (x) the loss of key personnel or the inability to manage our operations efficiently, (xi) problems with information management systems, manufacturing efficiencies and operations, (xii) insurance coverage issues, (xiii) the volatility of the stock market generally and of our stock specifically, and (xiv) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.
Contact:
Daniel Zwiren
dzwiren@optigenex.com
201 653 5195
SOURCE: Optigenex, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
OPGX_2-25-14_ETL_SMU.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment